The adverse outcome pathway (AOP) framework provides an alternative to traditional in vivo experiments for the risk assessment of chemicals. AOPs consist of a number of key events (KEs) linked by key event relationships (KERs) across a range of biological organization backed by scientific evidence. The first KE in the pathway is the molecular initiating event (MIE); the initial chemical trigger that starts an AOP. Over the last three years the AOP conceptual framework has gained a large amount of momentum in toxicology as an alternative to animal methods and so the MIE has come into the spotlight. What is an MIE? How can MIEs be measured or predicted? What research is currently contributing to our understanding of MIEs?
INTRODUCTION Toxicology risk assessment is undergoing a paradigm shift away from in vivo data and towards risk assessment frameworks that incorporate non-animal alternatives. Traditional in vivo toxicity studies form the basis of the majority of regulations globally that relate to assuring human and environmental safety. Increasingly however, there are societal, scientific and regulatory drivers to develop new ways of assuring safety that do not rely on data generation in animals. Rather than relying on apical toxicity endpoints in animals, new frameworks rely on an understanding of the mechanism of a chemical's toxicity in a relevant system which is thought to provide a more scientifically sound methodology on which to base risk assessment decisions. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   4 The National Research Council of the United States (NRC) opened the field for discussion in 2007, in an attempt to make toxicity testing quicker, less expensive, and more relevant to human exposures. 1 It pointed to a number of advances in the fields of biology and biotechnology that make it possible to feed data into new risk assessment approaches. These include physiologically based pharmacokinetic (PBPK) modelling methods, which provide a better understanding of how a compound behaves inside the body, and how much of it is able to get to a site of action. 2, 3 Furthermore, additional understanding of biological processes and the holistic nature of biology are being gained through -omics technologies [4] [5] [6] and systems biology. 7, 8 In silico methods also have their part to play in this paradigm shift. Informatics approaches such as (Quantitative)
Structure Activity Relationships ((Q)SARs) and Read-Across have the potential to make better use of existing data and target required testing to bring down the volume of in vivo studies required for a risk assessment. 9, 10 In addition to these, the coordination of the international scientific community, including collaboration between industry, academia and regulators, is of great importance for the advance of toxicity testing. 11, 12 These combined changes move toxicology away from a predominantly observational craft towards a science based on understanding.
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The adverse outcome pathway (AOP) framework for risk assessment is one approach to combine in silico, in vitro and in chemico methods with existing data to offer an alternative to animal experiments. Since it was first described in 2010, this framework has gained a lot of attention within the toxicology community. The Molecular Initiating Event (MIE) is the initial chemicalbiological interaction that starts the AOP. Understanding, characterizing and predicting MIEs will be of great importance to allow the AOP framework to realize its potential as a predictive tool and this key interaction is the focus of this work. With this review we aim to cover key MIE 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 5 research between the description of the AOP framework in 2010 and the end of 2015, giving an overview of how this concept has risen to prominence, and how it will aid toxicity risk assessment of the future.
This review is focused on the MIE within human health risk assessment, but MIEs are also relevant to ecotoxicology. Many of the ideas presented are equally applicable to ecotoxicology and human health, as the MIE occurs early in the AOP and can be common to a number of species.
Up to 2012
The first mention of a Molecular Initiating Event can be traced back to 2006. Schultz et al identified plausible MIEs based on the covalent interaction of soft electrophiles and biological molecules. 14 These interactions can lead to a number of toxicological endpoints including skin sensitization, DNA damage and immunological responses. These MIEs are considered appropriate targets for (Q)SAR modeling, and some models are presented linking molecular reactivity at a thiol moiety to aquatic toxicity and respiratory irritation endpoints. These reactivity-driven MIEs and their subsequent toxicity pathways were a key driver for the development of the AOP framework.
The modelling of chemical interactions between electrophiles and biological macromolecules was already established before the MIE. Work by Aptula and Roberts defined mechanistic domains for reactive aquatic toxicants, 15 and the same mechanistic domains were later applied to skin sensitizers. 16 This work due to a similarity in the MIE for these toxicological endpoints, the covalent modification of proteins. This MIE can be broken down based on the type of electrophilic chemistry that causes it. These categories were used as a basis for qualitative 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Figure 1 .
A number of case examples from ecotoxicology were also presented, including pathways for narcosis, photo-activated toxicity, the aryl-hydrocarbon receptor, activation of the estrogen receptor and impaired vitellogenesis. It was noted that a complete AOP with full elucidation of all steps is not necessary for the AOP to be a useful tool. Gaps in an AOP can be filled using weight-of-evidence or statistical approaches to establish links between exposure and adverse outcomes. Much effort can be saved by specifically targeting areas of the AOP designated as important for the assessment of a specific endpoint. The AOP framework for risk assessment complies with the NRC's vision for the future of toxicity testing, allowing for the identification of specific endpoints of regulatory concern and providing understanding of the toxicity mechanisms that cause them. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 8 tools such as the OECD QSAR Toolbox. 24 Enoch noted that, while the predictions made using these methods were only as good as the toxicological data that was sourced to build them, chemical categories are useful because they are mechanistically driven, and help to provide an understanding of why a chemical is able to undergo a specific interaction. This work aligns well with the MIE, as it too is mechanistically driven. This approach builds upon earlier work linking electrophilic reactivity to human health endpoints and brings it into an MIE perspective.
Originally, an electrophilic index was used to predict skin sensitization potential quantitatively using Read-Across QSAR techniques. 25 This was followed by the formation of electrophilic chemical groups for low molecular weight chemical compounds known to cause respiratory sensitization, 26 and these rules were later developed to link respiratory sensitization mechanisms to the electrophilic index. 27 These studies were published before the introduction of the MIE and AOP framework, but fit well with the ideas presented since, and conform to similar ideals. • Chemical interaction at a molecular target leading to a particular adverse outcome.
• The seminal interaction (e.g. DNA-binding, protein oxidation, or receptor/ligand interaction) of a chemical with a biological target.
The OECD recognized that the development and elucidation of AOPs will require contributions of multiple scientific fields, covering chemistry, biology and toxicology. Standardization of terms used in AOPs is necessary to allow these fields to communicate and develop the framework into the future.
Developments in 2013
In In a study analogous to an MIE approach to carcinogenicity, Benigni et al reviewed and combined a number of 2D SARs. 33 Carcinogenicity is broken down by mechanism of action to for an expansion of this approach, increasing its impact.
Casalegno and Sello published a similar study predicting mode of action of environmental toxicants by structural similarity. 34 These models were based not on experimental data, but on structural features alone. This approach relies on the fact that the interaction between wellcharacterized molecules and an ill-defined biological target depends on the chemistry of both parts. Casalegno and Sello note that a lack of understanding of the modes of action associated with ecotoxicology makes this a difficult study, as poorly defined modes of action, such as narcosis or electrophilicity, are often used. Both a better understanding of the complex mechanisms behind ecotoxicity and a greater availability of data are required to make an approach such as this practically useful.
Gutsell and Russell's 2013 analysis, 35 shows that chemistry is key to understanding the MIE and also has other important roles to play in the AOP framework. will be able to make risk assessment, based on chemistry alone, a reality. A visualization of this wet/dry cycle is shown in Figure 2 .
AOP approaches were reviewed in mid-2013 by Vinken. 36 This review covered the development of AOPs from key building blocks, and several well-developed examples were discussed, including skin sensitization, cholestasis, liver fibrosis and liver steatosis. Vinken also discussed the key roles of (Q)SARs and in vitro tests to predict and to inform pathways. Key challenges in the field are presented, including compliance with the complexity of toxicology, the inclusion of dose-response relationships in pathway development, the integration of exposure and toxicokinetic data, and the transparent and objective evaluation of the outcomes.
Martin et al presented the use of mode of action to categorize aquatic toxicants and build models. 37 This study involved modes of action including receptor agonism, enzyme inhibition, chemical reactivity and biosystem disturbance. Martin notes that while the models provide promising results (overall prediction accuracy 85%), further categorization of the more general modes of action, such as chemical reactivity, into smaller structural-mechanism groupings (as may be expected with a more MIE-like analysis) should improve predictivity.
A key issue, particularly in ecotoxicology, is the extrapolation of data points between species during chemical risk assessment. This also applies to KEs within the AOP -including the MIE.
LaLone et al described a quantitative tool for the extrapolation of MIEs between species using bioinformatics approaches and an understanding of the target species biology. 38 The conservation of KEs across several AOPs is an important simplification of biology within the AOP approach.
If some of these KEs can also be preserved across species, this will aid the difficult task of ecotoxicological risk assessment, due to the diverse nature of the environment, and provide An entirely quantitative risk assessment using the AOP framework was attempted by Maxwell et al at the end of 2013. 39 The skin sensitization AOP was one of the first AOPs to be considered well developed within the field. 28 Maxwell used KEs from early in the pathway to provide input parameters for the "total haptenated protein" model, with the "CD8+ T cell response" model providing predictions for KEs late in the pathway and for the overall adverse outcome (allergic contact dermatitis).
Chemical dose applied to the skin is linked to the amount of total haptenated protein using mathematical models, taking into account the pharmacokinetic steps as the chemical travels from skin surface to the protein. These include clearance mechanisms, metabolism, and other chemical transformations. The CD8+ T cell response model aims to predict the number of hapten-specific human CD8+ central memory T cells generated following repeated exposure to a chemical sensitizer, using inputs from the total haptenated protein model. Maxwell suggests that, once a threshold of hapten-specific human CD8+ central memory T cells is exceeded, an inflammatory response will manifest upon re-exposure to a sensitizer. These models were at the time in the early stages of development. However, by benchmarking them against clinical data it should be possible to predict whether a specific skin exposure will cause the required hapten-specific T cell response required to cause an adverse effect upon re-exposure.
In November 2013, Wu et al published a decision tree to predict Developmental And
Reproductive Toxicity (DART) endpoints. 40 This in silico assessment was made without use of an AOP framework and shows the complexity associated with predicting across multiple 13 endpoints and toxicity pathways. Development of the decision tree identified a number of important structural fragments that can enhance the understanding behind DART modes of action using MIEs. The decision tree itself allows for rapid screening of potential DART.
Developments in 2014
In January 2014, Caldwell et al published an integrated approach for prioritizing pharmaceutical ingredients for ecotoxicological risk assessment using an AOP-informed approach. 41 Mammalian pharmacology data and pharmaceutical usage data were combined to provide a prioritization for risk assessment and advanced research. Prioritization of assessment is particularly important in ecotoxicology where the amount of data available to construct predictive models is often limited.
In 2014 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Following their previous work into reactivity-driven MIEs for DNA modification, 23 Nelms et al used a similar approach to develop a collection of structural alerts built into an in silico profiler for systemic toxicity of hair dyes. 47 Repeat dose toxicity studies for 94 hair dyes were used, and chemicals were grouped based on structural similarity. Four categories were identified for hair dyes containing a 2-nitroaminobenzene, a 4-nitroaminobenzene, an aromatic azo, or an anthraquinone moiety. Nelms went on to develop a mechanistic hypothesis for each of the four groups, and refined structural alerts were presented as an in silico profiler, covering proquinones, quinones, meta-substituted benzenes and aromatic azo compounds. This profiler assigned 56 of the 94 chemicals in the dataset to a mechanism-based chemical category. The reactivity-driven nature of these toxicity mechanisms may also allow the alerts to be used in mitochondrial toxicity, and this was also discussed by Nelms. This paper emphasizes that approaches like this do not attempt to predict oral repeat-dose toxicity, but instead a particular MIE that might be responsible for an AOP leading to chronic toxicity. Detailed studies such as this are required to develop models for MIEs, and to identify the MIEs themselves, as at this time they are generally poorly understood at a mechanistic level. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   16 above. 28 These discussions highlight the significance of the MIE and the important roles different areas of toxicology will play in gaining an understanding of these key interactions.
Chemistry's key role in MIE and AOP research was further highlighted by Allen et al. 49 AOP networks for a number of well-understood toxicants were developed using literature searches.
These case studies were used to unify existing definitions of the MIE and concluded that an MIE is the initial interaction between a molecule and a biomolecule or biosystem that can be causally linked to an outcome via a pathway. The role of the MIE in AOP research and toxicity risk assessment was also discussed, including a framework in which an in silico (Q)SAR relates molecular properties of a novel compound to an MIE, and any associated AOP can then infer an expected adverse outcome for the compound, as shown in 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 As has already been discussed, 23,33,47 structural alerts play a key part in predictive toxicology.
Chemotypes were introduced in 2014 as a new way of coding such alerts, and Chemotyper is software that allows them to be searched against a dataset. 53 Chemical substructure mark-up language (CSRML), an XML-based code, is used to capture chemotypes. This language allows for the inclusion of physico-chemical properties and descriptors as well as 2D structure, allowing greater flexibility of constructed models.
Developments in 2015
In February 2015, a report from FutureTox II (held in January 2014) was published by Knudsen et al 54 The goals of this meeting were to discuss the progress towards the NRC's vision for toxicity testing in the 21st century 1 and in silico and in vitro methodologies featured heavily.
AOPs were discussed as a key concept. Despite OECD guidelines which state that an AOP links a single MIE and an effect at a high level of biological organization, it is accepted that a single MIE may lead to several AOPs and an adverse effect may be associated with several MIEs. AOP networks can capture the complexity of the biological sphere far better; and the MIE is identified as an important KE that can be used to screen compounds to identify the AOPs that are likely to be of most interest.
The difficulty associated with IVIVE has already been mentioned. 50 Angrish et al presented an approach to bridging the IVIVE gap in high throughput screening (HTS) assays. 55 Using an ultra-sensitive gas-phase probe molecule, they aim to measure effects on metabolism that will link through to understood in vivo outcomes. As an example, the pharmacokinetic parameters associated with a cytochrome-2A6-driven metabolism were identified in order to measure the effect of a toxicant indirectly by observing a metabolite: methyl tertiary-butyl ether. 57 number of rotational bonds, molecular weight and logarithm of the water-octanol partition coefficient) were used to give an insight into the physico-chemical applicability domain for retinoic acid receptor binding. These early approaches towards MIE tools are designed not to replace in vitro testing or be a complete in silico model, but rather to provide a rapid screen and prioritization methodology to assist in risk assessment.
The importance and potential impact of AOPs as a framework in non-animal risk assessment was reviewed by Burden et al in March 2015. 58 Key to the recent paradigm shift in toxicity testing is the Replacement, Refinement and Reduction of animal methods -also known as the 3Rs. 59 The AOP framework provides an important scientific basis on which new risk assessment practices can be built -as no single alternative testing method will replace an in vivo model like-for-like.
One such combined approach could involve the prediction of adverse effects based on a predetermined MIE. Concerted efforts to collect, integrate and organize data from relevant sources across scientific disciplines will be required to reap the benefits of such a coherent framework.
Regulatory input is also required, to guide the use of AOPs in risk assessment decision-making.
While single AOPs are considered the building blocks of AOP development, they are not a complete representation of complex biological systems when considered in isolation. AOP networks would seem to provide a solution to this, as described by Knapen et al. 60 AOPs are Several case studies are given and the importance of using weight-of-evidence-based approaches to analyze AOPs discussed. To ensure transparency and promote consistency across AOP research, these kinds of confidence assessments must be carried out and analyzed. This ultimately will lead to enhanced rigor, transparency and reproducibility for AOP confidence assessment, improving confidence in AOPs themselves. 
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This particular area of AOP research has been further explored by Yauk et al 62 The AOP for alkylation of DNA in male premeiotic germ cells leading to heritable mutations was examined in depth in order to establish its biological plausibility and the empirical evidence that supports it.
In turn each KE was considered, examining how the KE works and how it was measured or detected experimentally. KERs are then examined, looking at how the biological processes work, the weight of evidence that supports them, any uncertainties or inconsistencies in their supporting data, and the level of quantitative understanding of the linkage they provide.
Following this analysis the KEs and KERs are assessed as having strong, moderate, or low levels of confidence. A particular challenge, noted by Yauk, in this AOP development was the gathering of appropriate dose-response data for assessment of the Bradford-Hill considerations from historical studies that were not conducted with this type of research in mind and which are time-consuming to interpret. The AOP framework should be able to overcome this hurdle, since the more KEs and KERs are isolated, the more likely it is that new AOPs will incorporate KEs and KERs which have already been characterized, and so the process will speed up.
Dent et al discussed the AOP for anti-androgenic activity in humans in a similar level of detail.
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The aim was to establish the status of the tools and approaches being put towards a non-animal risk assessment for this AOP. A particular point noted here was the high level of uncertainty associated with the extrapolation of data from effects seen in high dose animal studies to the much lower exposures anticipated for humans. Therefore, the exposure of the human to the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 21 endpoint caused by the exposure of humans to metals and mixtures of metals, specifically lead, arsenic, cadmium and manganese. 64 An AOP was developed and assessed using the BradfordHill considerations. This AOP linked the activation of extracellular-signal-related kinase by metals to an increase in levels of cellular calcium ions and neurological disorders including deficits in learning and cognition. It is important that MIE and AOP approaches can be utilized in these different situations to increase their impact in toxicology.
Following on from previous work into in silico models for reactivity driven MIEs for DNA They are thought to be conserved in humans, allowing the extrapolation of the existing in vivo data for use in human toxicology. Similarities in the mechanism of action across several phyla and the high homology between mouse and human tubulin provide evidence for this. This MIE presents an interesting case, in which in silico, in chemico, in vitro and in vivo studies may all be able to be used to predict the impact of an MIE in humans. KEs requiring prediction will continue to demand more from (Q)SAR scientists. It is particularly highlighted that AOPs must be kept in mind during the development of new (Q)SARs, promoting the development of tools which model small steps between KEs and not large leaps over many complex levels of biological organization.
At the end of 2015 the SEURAT-1 initiative closed and the EU-ToxRisk program, 70 was initiated early in 2016 to continue driving mechanism-based toxicity testing for risk assessment in the 21st century.
CONCLUSIONS
As toxicology moves away from animal experiments and towards in silico, in vitro and in chemico methods, as well as combinations of these, deeper understanding and new tools are required. The AOP framework provides a powerful method to do this. As arguably the most important key event within the AOP, a greater knowledge of MIEs will be vital to the success of this framework. A greater understanding of the MIE must be developed, and tools must be constructed to allow MIEs to be predicted, and measured for novel compounds.
The MIE sits on the boundary between biology and chemistry, and as such both these fields have important roles to play in its development. This has been shown in this review, with a number of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 publications coming from both a chemical and biological background. In silico, in vitro and in chemico methods all have a part to play, and this is also represented.
As the first KE in an AOP, the MIE has a key role to play in the understanding of toxicity in both humans and animals. As a result the MIE is applicable in both human health and ecotoxicology risk assessment. The MIE and AOP provide a template for the coming together of these fields, as it is expected that some, but not all, of the KEs and KERs will be shared across species. One of the main drives of the AOP framework is for better risk assessment procedures, and this collaboration can help by providing additional data and understanding previously confined to their fields.
As outlined above a number of MIEs have now been characterized. This allows us to begin grouping these interactions based on their chemistry. The earliest studied MIEs were covalent bond forming reactions between chemicals and biological molecules. These MIEs include the reactions of electrophilic chemicals with DNA molecules, 23 and the covalent modification of skin proteins. 43 MIEs such as these can lead to toxicological endpoints such as allergic contact dermatitis, 39 genotoxicity, and immunological disorders. 39 A second category of MIEs is those which involve non-covalent binding of a chemical to a biological target such as a receptor or enzyme. These can include the activation of PPARγ, 45 or the agonism or antagonism of nuclear receptors, 66 both leading to liver steatosis, the inhibition of complexes of the mitochondrial electron transport chain leading to mitochondrial dysfunction, 65 and the binding of chemicals to tubulin leading to teratogenic endpoints.
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A final category of MIEs is for those chemicals that do not directly interact with a specific biomolecule, but rather cause a disturbance in cellular or organelle biosystems. Biosystem 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 disturbance has been alluded to in several cases 37, 49 and provides an MIE category for the narcosis mode of action often used in ecotoxicology which is associated with membrane disruption. 34 Other biosystem disturbance MIEs include chemicals which act as protonophores or redox cyclers leading to mitochondrial toxicity endpoints.
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The impact of the MIE and AOP framework has undoubtedly increased over the last three years, with the number of publications contributing to the area increasing each year. The understanding gained, and tools developed so far, represent an important platform for future development, with the ultimate aim being a tool for quantitatively predicting the impact of a chemical on a human or ecotoxicological target. The emergence of the MIE highlights the idea that chemical understanding is critical in modelling, and that mechanistic local modelling is key to providing the best predictions. Feeding an MIE prediction tool into a combined AOP framework, incorporating exposure, absorption, distribution, metabolism and excretion (ADME), and an understanding of downstream effects along the AOP will be able to provide a genuine alternative for toxicology: reliable risk assessment entirely free of in vivo experiments.
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